BioNTech takes over cancer immunotherapy platformMainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals. more ➔
Nanosyrinx raises £6.2m to validate drug delivery platformCoventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities. more ➔
€26m financing for ISA PharmaceuticalsDutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers. more ➔
Unilever licences Arzeda Inc.s enzyme technologyAs part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon. more ➔
Novo Nordisk Novo Nordisk invests in amyloidosis pipelineDanish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy. more ➔
Sanofi Sanofi invests heavily in multiple myeloma pipeline Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment. more ➔
Bio-Me raises NOK10mOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round. more ➔
NFL Biosciences goes public, raises €5mFrench biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris. more ➔
Promethera bags €20m for liver failure treatmentWith a €20m financing round under its belt, Promethera Therapeutics is poised to start its Phase IIb study for its stem cell therapy treating liver failure. more ➔
Novalis Biotech closes biotech fund at €25mEarly-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at €25m to drive growth of translational medicine start-ups. more ➔
Novo Nordisk
Sanofi
